Engineered to mimic the complementary effects of GLP-1 and glucagon without dose titration in reported protocols.
Also known as: ALT-801
Part of the Metabolic & GLP-1 peptides cluster
Overview
Pemvidutide (ALT-801) is an investigational dual GLP-1/glucagon receptor agonist developed by Altimmune and studied in clinical trials for obesity and MASH. It illustrates how a lipidated peptide can be designed for once-weekly dosing. It is not authorized by Health Canada, and this page is educational only.
Source & context
Biological / chemical source: Synthetic peptide with a lipid moiety engineered for weekly subcutaneous dosing
Primary research or clinical context: Investigational compound (Altimmune); studied in trials for obesity and metabolic dysfunction-associated steatohepatitis — not authorized by Health Canada
Design and dosing
Pemvidutide is a lipidated peptide that activates both the GLP-1 and glucagon receptors. In the developer's framework, GLP-1 activity supports appetite and glucose signalling while glucagon activity is associated with energy expenditure and hepatic lipid handling. The lipid moiety extends its half-life to support once-weekly subcutaneous administration in reported trials.
Research and regulatory status
Pemvidutide has been evaluated in phase 2 obesity and liver trials. It remains investigational and is not authorized by Health Canada. This educational summary describes its mechanism and development history without asserting any therapeutic benefit; decisions about metabolic health belong with a licensed clinician.
FAQ about Pemvidutide
What is Pemvidutide?+
Pemvidutide (ALT-801) is an investigational dual GLP-1/glucagon receptor agonist developed by Altimmune and studied in clinical trials for obesity and MASH. It illustrates how a lipidated peptide can be designed for once-weekly dosing. It is not authorized by Health Canada, and this page is educational only.
Is Pemvidutide an approved medicine?+
Pemvidutide is discussed here as a research / educational topic. Investigational compound (Altimmune); studied in trials for obesity and metabolic dysfunction-associated steatohepatitis — not authorized by Health Canada. This is not medical advice.
What is the typical length of Pemvidutide?+
Pemvidutide is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.